AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 95
- 主要终点
- Metastatic Breast Cancer (MBC) understanding
研究概览
简要总结
This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who are 18 or older, either female or male, and who have not received more than 1 type of treatment from the time metastases were discovered, metastasi(e)s has just been diagnosed or their disease has come back (disease relapse). Biopsy samples from both the primary and metastatic (or relapsed) tumor will be collected for central analyses, together with blood, serum and plasma samples. Any samples not analyzed immediately will be stored in an independent bio-repository to enable future (not yet defined) research aimed at better understanding metastatic breast cancer.
In summary, the main objectives of AURORA are to better understand the genetic aberrations in metastatic breast cancer and to discover the mechanisms of response or resistance to therapy, in order to ultimately identify the "right therapy for each individual patient". At the same time, patients with genetic aberrations that are being targeted by new drugs in development will be offered the possibility to participate in clinical trials, when approved and available in their countries. Ultimately, the aim of AURORA is to improve the outcomes of all patients diagnosed with metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or male ≥ 18 years with diagnosis of locally recurrent/advanced BC not amenable to treatment with curative intent or MBC who have not received more than 1 line of systemic therapy (any type) in the metastatic setting.
- •Under protocol 4.0, eligible patients will be limited to locally recurrent/advanced breast cancer not amenable to treatment with curative intent or MBC with:
- •histopathology-confirmed TNBC as defined by ER <1% and HER2 negative following ASCO-CAP guidelines
- •ILC (either based on ILC morphology or negative E-cadherin expression confirmed by IHC). Mixed ILC/invasive ductal carcinoma are not eligible for the ILC cohort.
- •late relapse BC (any subtype). Late relapse is defined as a patient with a radiologic or histologic confirmation of advanced or MBC relapse > 10 years from the primary BC diagnosis.
- •Written informed consent prior to registration into the program.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or
- •Availability of primary tumor tissue for research purposes.
- •Patient must have a metastatic lesion accessible for biopsy and must agree with the biopsy procedure.
- •Up until protocol 3.0, up to 100 patients with bone-only metastasis have been included without a metastatic biopsy, if plasma samples have been collected at screening, and if the patient met all other eligibility criteria.
- •In protocol 4.0, metastatic tumor biopsies from bone lesions will be accepted provided that the chosen site of biopsy was not previously irradiated.
- •Brain tissue is accepted if it is obtained through surgical excision not planned for AURORA, but as part of the routine clinical practice.
- •The biopsy of the metastatic lesion must be conducted either at the initial diagnosis of the BC relapse before the initiation of 1st line systemic therapy or at the 1st disease progression before initiation of a second line systemic treatment. There is no restriction in the type of therapeutic modality considered as 1st line systemic treatment, which can consist of any type of treatment administered after the diagnosis of the advanced BC relapse till the 1st disease progression thereafter.
- •Biopsies obtained during routine clinical practice are accepted if both formalin-fixed paraffin-embedded (FFPE) and Frozen Tissue (FT) blocks were collected concurrently from the same metastatic lesion and if collected at the pre-specified timelines for AURORA.
- •Availability of a whole blood, serum and plasma samples collected at the time of screening.
- •Patient agrees to provide blood samples at regular intervals, from the screening as well as during the follow-up phase of the program.
排除标准
- •The patient has received more than 1 line of systemic therapy (any type) in the metastatic setting.
- •Patients who have received prior palliative radiotherapy to the only site that is accessible to biopsy.
- •Presence of severe hematopoietic, renal, and/or hepatic dysfunction, including but not restricted to albumin < 3 g/dl.
- •Known increased risk of hemorrhage during biopsy procedure, as evaluated by the treating physician.
- •Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin.
研究组 & 干预措施
metastatic lesion biopsy
biopsy of metastatic lesion will be performed at program inclusion or maximum 6 months prior to inclusion. Sample of primary tumor must be available at inclusion.
干预措施: metastatic lesion biopsy (Procedure)
结局指标
主要结局
Metastatic Breast Cancer (MBC) understanding
时间窗: 1 year after end of acrrual
To improve the understanding of locally recurrent/advanced BC and MBC by using high-throughput technologies on primary, metastatic, as well as plasma ctDNA samples, to explore tumor heterogeneity, clonal evolution and transcriptional changes associated with mutational and copy number variation (CNV) patterns.
次要结局
- Feasibility of implementing a global molecular screening platform for MBC(1 year after end of accrual)
- Identification of "exceptional responders" and "rapid progressors"; the outlier patients(1 year after end of accrual and subsequently during follow up period of 10 years)
- Patients' prognosis determination(1 year after end of accrual and subsequently during follow up period of 10 years)
- Correlation between molecular alterations and standardly assessed efficacy endpoints(1 year after end of accrual and subsequently during follow up period of 10 years)
- Patient identification to match with biomarker-driven clinical trials(on ongoing basis during 3 years' patient recruitment)
- Building new therapeutic hypotheses(1 year after end of accrual and subsequently during follow up period of 10 years)